Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ACTUATE THERAPEUTICS, INC.ACTU · Entity 7370 | Director | May 21, 2026 | May 22, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ACTUATE THERAPEUTICS, INC.
Report date May 21, 2026 · Filed May 22, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $2.42 · Expires 2036-05-21 | Direct | 15,000 |
Reported balance
After 2026-05-21 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-21 · Grant · Acquired 15,000 · Balance 15,000 F1: Options will vest in full on the anniversary of the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: Options will vest in full on the anniversary of the grant date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Apexigen, Inc.
Report date August 23, 2023 · Filed August 25, 2023
Section 16 reporting ended · disclosed 2023-08-25. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.65 · Expires 2032-09-29 | Direct | 0 |
Reported balance
After 2023-08-23 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-08-23 · Disposition to issuer · Disposed 100,000 · Balance 0 F1: The shares subject to the option vest in three equal annual installments beginning on July 29, 2023. Pursuant to an Agreement and Plan of Merger, dated as of May 23, 2023, by and among the Issuer, Pyxis Oncology, Inc. ("Pyxis"), and Ascent Merger Sub Corp., at the effective time of the merger (the "Effective Time"), the option was assumed by Pyxis and converted into an option to purchase 17,250 shares of Pyxis common stock at an exercise price of $15.37 per share. In accordance with the reporting person's equity award agreement, vesting of the unvested shares underlying the option accelerated in full at the Effective Time. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to the option vest in three equal annual installments beginning on July 29, 2023. Pursuant to an Agreement and Plan of Merger, dated as of May 23, 2023, by and among the Issuer, Pyxis Oncology, Inc. ("Pyxis"), and Ascent Merger Sub Corp., at the effective time of the merger (the "Effective Time"), the option was assumed by Pyxis and converted into an option to purchase 17,250 shares of Pyxis common stock at an exercise price of $15.37 per share. In accordance with the reporting person's equity award agreement, vesting of the unvested shares underlying the option accelerated in full at the Effective Time.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 21, 2026 Filed May 22, 2026 20:15 UTC | ACTUATE THERAPEUTICS, INC. ACTU · Entity 7370 | GrantStock Options · Derivative | 15,000 | $0.00 Strike: $2.42 | $0.00 |
DisclosureSEC source: 0001683168-26-004260 · ownership.xml · derivative · entry 1 Zabrowski Dan · CIK 0001940818 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2036-05-21 F1 · derivative.exercise_date: Options will vest in full on the anniversary of the grant date. Read SEC document |
| May 22, 2025 Filed May 23, 2025 20:05 UTC | ACTUATE THERAPEUTICS, INC. ACTU · Entity 7370 | GrantStock Options · Derivative | 15,000 | $0.00 Strike: $10.10 | $0.00 |
DisclosureSEC source: 0001683168-25-003990 · ownership.xml · derivative · entry 1 Zabrowski Dan · CIK 0001940818 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2035-05-22 F1 · derivative.exercise_date: Options will vest in full on the anniversary of the grant date. Read SEC document |
| August 12, 2024 Filed Aug 14, 2024 23:30 UTC | ACTUATE THERAPEUTICS, INC. ACTU · Entity 7370 | GrantNon-Qualified Stock Options · Derivative | 15,000 | $0.00 Strike: $8.00 | $0.00 |
DisclosureSEC source: 0001104659-24-089797 · tm2421559-8_4.xml · derivative · entry 1 Zabrowski Dan · CIK 0001940818 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2034-08-12 F1 · derivative.exercise_date: 15,000 stock options granted upon the effectiveness of the registration statement for the issuer's initial public offering on August 12, 2024, which vest in full on the first anniversary of the grant date. Read SEC document |
| August 23, 2023 Filed Aug 25, 2023 19:42 UTC | Apexigen, Inc. APGN · Entity 110214 | Disposition to issuerStock Option (right to buy) · Derivative | 100,000 | Not disclosed Strike: $2.65 | Not disclosed |
DisclosureSEC source: 0001209191-23-047456 · doc4.xml · derivative · entry 1 Zabrowksi Dan · CIK 0001940818 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 100,000 shares Expires 2032-09-29 F1 · price: The shares subject to the option vest in three equal annual installments beginning on July 29, 2023. Pursuant to an Agreement and Plan of Merger, dated as of May 23, 2023, by and among the Issuer, Pyxis Oncology, Inc. ("Pyxis"), and Ascent Merger Sub Corp., at the effective time of the merger (the "Effective Time"), the option was assumed by Pyxis and converted into an option to purchase 17,250 shares of Pyxis common stock at an exercise price of $15.37 per share. In accordance with the reporting person's equity award agreement, vesting of the unvested shares underlying the option accelerated in full at the Effective Time. F1 · derivative.exercise_date: The shares subject to the option vest in three equal annual installments beginning on July 29, 2023. Pursuant to an Agreement and Plan of Merger, dated as of May 23, 2023, by and among the Issuer, Pyxis Oncology, Inc. ("Pyxis"), and Ascent Merger Sub Corp., at the effective time of the merger (the "Effective Time"), the option was assumed by Pyxis and converted into an option to purchase 17,250 shares of Pyxis common stock at an exercise price of $15.37 per share. In accordance with the reporting person's equity award agreement, vesting of the unvested shares underlying the option accelerated in full at the Effective Time. Read SEC document |
| September 29, 2022 Filed Oct 3, 2022 19:06 UTC | Apexigen, Inc. APGN · Entity 110214 | GrantStock Option (right to buy) · Derivative | 100,000 | $0.00 Strike: $2.65 | $0.00 |
DisclosureSEC source: 0001209191-22-051971 · doc4.xml · derivative · entry 1 Zabrowksi Dan · CIK 0001940818 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2032-09-29 F1 · derivative.exercise_date: The shares subject to the option vest in three equal annual installments beginning on July 29, 2023. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.